State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital, The Fourth Military Medical University, Xi'an, PR China.
Department of Pathology, No. 971 Hospital of People's Liberation Army Navy, Qingdao, PR China.
J Pathol. 2023 Oct;261(2):210-226. doi: 10.1002/path.6167. Epub 2023 Aug 11.
Therapeutic resistance is a notable cause of death in patients with ovarian carcinoma. Polyploid giant cancer cells (PGCCs), commonly arising in tumor tissues following chemotherapy, have recently been considered to contribute to drug resistance. As a type III deacetylase, Sirtuin1 (SIRT1) plays essential roles in the cell cycle, cellular senescence, and drug resistance. Accumulating evidence has suggested that alteration in its subcellular localization via nucleocytoplasmic shuttling is a critical process influencing the functions of SIRT1. However, the roles of SIRT1 subcellular localization in PGCC formation and subsequent senescence escape remain unclear. In this study, we compared the differences in the polyploid cell population and senescence state of PGCCs following paclitaxel treatment between tumor cells overexpressing wild-type SIRT1 (WT SIRT1) and those expressing nuclear localization sequence (NLS)-mutated SIRT1 (SIRT1 ). We investigated the involvement of cytoplasmic SIRT1 in biological processes and signaling pathways, including the cell cycle and cellular senescence, in ovarian carcinoma cells' response to paclitaxel treatment. We found that the SIRT1 tumor cell population contained more polyploid cells and fewer senescent PGCCs than the SIRT1-overexpressing tumor cell population. Comparative proteomic analyses using co-immunoprecipitation (Co-IP) combined with liquid chromatography-mass spectrometry (LC-MS)/MS showed the differences in the differentially expressed proteins related to PGCC formation, cell growth, and death, including CDK1 and CDK2, between SIRT1 and SIRT1 cells or PGCCs. Our results suggested that ovarian carcinoma cells utilize polyploidy formation as a survival mechanism during exposure to paclitaxel-based treatment via the effect of cytoplasmic SIRT1 on PGCC formation and survival, thereby boosting paclitaxel resistance. © 2023 The Pathological Society of Great Britain and Ireland.
治疗抵抗是卵巢癌患者死亡的一个显著原因。多倍体巨癌细胞(PGCCs)在化疗后肿瘤组织中常见,最近被认为有助于药物抵抗。作为一种 III 型去乙酰化酶,Sirtuin1(SIRT1)在细胞周期、细胞衰老和药物抵抗中发挥着重要作用。越来越多的证据表明,通过核质穿梭改变其亚细胞定位是影响 SIRT1 功能的一个关键过程。然而,SIRT1 亚细胞定位在 PGCC 形成和随后的衰老逃逸中的作用尚不清楚。在这项研究中,我们比较了过表达野生型 SIRT1(WT SIRT1)和核定位序列(NLS)突变型 SIRT1(SIRT1)的肿瘤细胞在紫杉醇处理后 PGCC 形成和衰老状态的多倍体细胞群的差异。我们研究了细胞质 SIRT1 在卵巢癌细胞对紫杉醇治疗的反应中参与包括细胞周期和细胞衰老在内的生物学过程和信号通路的情况。我们发现,SIRT1 肿瘤细胞群体比 SIRT1 过表达肿瘤细胞群体含有更多的多倍体细胞和更少的衰老 PGCCs。使用 Co-IP 结合液相色谱-质谱/质谱(LC-MS/MS)的比较蛋白质组学分析显示了与 PGCC 形成、细胞生长和死亡相关的差异表达蛋白,包括 CDK1 和 CDK2,在 SIRT1 和 SIRT1 细胞或 PGCCs 之间存在差异。我们的结果表明,卵巢癌细胞通过细胞质 SIRT1 对 PGCC 形成和存活的影响,利用多倍体形成作为其在紫杉醇为基础的治疗中暴露时的一种生存机制,从而增强了紫杉醇的耐药性。